Live Breaking News & Updates on Immagene Biopharmaceuticals

Stay updated with breaking news from Immagene biopharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Izokibep Improves Multiple PsA Symptoms in Phase 2 Study

Greater percentages of patients treated with one of two doses of the novel IL-17 blocker achieved an ACR 50 response vs placebo. ....

United States , Frank Behrens , Pharma Advanced Research , European Congress , Boehringer Ingelheim , American College Of Rheumatology , Goethe University Frankfurt , Gilead Sciences Inc , Medscape Professional Network , Bristol Myers Squibb , American College , Psoriasis Area , Severity Index , Immagene Biopharmaceuticals , Two Doses , Psoriatic Arthritis , Leeds Enthesitis , Psoriatic Impact , Gilead Sciences , Advanced Research , Nordic Pharma , Medscape Professional , Clinical Research , Clinical Trials , Linical Studies , Healthcare And Medical Technology ,